All news

BlackRock reports sole voting power over 5.44M shares in its amended Fulcrum Therapeutics (FULC) stake disclosure.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

BlackRock Portfolio Management LLC has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Fulcrum Therapeutics, Inc. (FULC), reporting beneficial ownership of 6,155,437 common shares, representing 8.1% of the class. The filing specifies that BlackRock holds sole voting power over 5,436,791 shares and sole dispositive power over all 6,155,437 shares, with no shared voting or dispositive power.

Read original source

FULC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.